162 related articles for article (PubMed ID: 25560531)
1. Targeted therapies: new standard for ALK-positive NSCLC.
Hutchinson L
Nat Rev Clin Oncol; 2015 Feb; 12(2):66. PubMed ID: 25560531
[No Abstract] [Full Text] [Related]
2. First-line crizotinib in ALK-positive lung cancer.
Solomon BJ; Mok T
N Engl J Med; 2015 Feb; 372(8):782. PubMed ID: 25693021
[No Abstract] [Full Text] [Related]
3. First-line crizotinib in ALK-positive lung cancer.
Alkan A; Köksoy EB; Utkan G
N Engl J Med; 2015 Feb; 372(8):781-2. PubMed ID: 25693023
[No Abstract] [Full Text] [Related]
4. First-line crizotinib in ALK-positive lung cancer.
Tural D; Kilickap S
N Engl J Med; 2015 Feb; 372(8):781. PubMed ID: 25693022
[No Abstract] [Full Text] [Related]
5. Cancer-drug discovery--let's get ready for the next period.
Longo DL
N Engl J Med; 2014 Dec; 371(23):2227-8. PubMed ID: 25470699
[No Abstract] [Full Text] [Related]
6. Crizotinib in ALK-positive lung cancer.
Girard N
Lancet Oncol; 2012 Oct; 13(10):962-3. PubMed ID: 22954506
[No Abstract] [Full Text] [Related]
7. Hope without hype: EML4-ALK inhibition for treatment of lung cancer.
Govindan R
Lancet Oncol; 2011 Oct; 12(11):983-4. PubMed ID: 21933750
[No Abstract] [Full Text] [Related]
8. Alectinib surpasses crizotinib for untreated ALK-positive NSCLC.
Gilbert JA
Lancet Oncol; 2017 Jul; 18(7):e377. PubMed ID: 28625556
[No Abstract] [Full Text] [Related]
9. [Is chemotherapy still an option in oncogene-addicted non-small cell lung cancer? No].
Girard N
Bull Cancer; 2015 Jun; 102(6 Suppl 1):S96-9. PubMed ID: 26118885
[TBL] [Abstract][Full Text] [Related]
10. Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study.
Duruisseaux M; Besse B; Cadranel J; Pérol M; Mennecier B; Bigay-Game L; Descourt R; Dansin E; Audigier-Valette C; Moreau L; Hureaux J; Veillon R; Otto J; Madroszyk-Flandin A; Cortot A; Guichard F; Boudou-Rouquette P; Langlais A; Missy P; Morin F; Moro-Sibilot D
Oncotarget; 2017 Mar; 8(13):21903-21917. PubMed ID: 28423535
[TBL] [Abstract][Full Text] [Related]
11. Rapid response of brain metastasis to crizotinib in a patient with ALK rearrangement-positive non-small-cell lung cancer.
Kaneda H; Okamoto I; Nakagawa K
J Thorac Oncol; 2013 Apr; 8(4):e32-3. PubMed ID: 23486271
[No Abstract] [Full Text] [Related]
12. New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer.
Cameron L; Solomon B
Curr Treat Options Oncol; 2015 Oct; 16(10):49. PubMed ID: 26318457
[TBL] [Abstract][Full Text] [Related]
13. Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus.
Cappuzzo F; Moro-Sibilot D; Gautschi O; Boleti E; Felip E; Groen HJ; Germonpré P; Meldgaard P; Arriola E; Steele N; Fox J; Schnell P; Engelsberg A; Wolf J
Lung Cancer; 2015 Feb; 87(2):89-95. PubMed ID: 25576294
[TBL] [Abstract][Full Text] [Related]
14. Acquired resistance to the ALK inhibitor crizotinib in the absence of an ALK mutation.
Costa DB; Kobayashi S
J Thorac Oncol; 2012 Mar; 7(3):623-5. PubMed ID: 22334013
[No Abstract] [Full Text] [Related]
15. Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK-Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls.
Tan DS; Araújo A; Zhang J; Signorovitch J; Zhou ZY; Cai X; Liu G
J Thorac Oncol; 2016 Sep; 11(9):1550-7. PubMed ID: 27288979
[TBL] [Abstract][Full Text] [Related]
16. Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions.
Cameron L; Solomon B
Drugs; 2015 Jul; 75(10):1059-70. PubMed ID: 26076736
[TBL] [Abstract][Full Text] [Related]
17. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
Rodig SJ; Shapiro GI
Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
[TBL] [Abstract][Full Text] [Related]
18. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
O'Bryant CL; Wenger SD; Kim M; Thompson LA
Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
[TBL] [Abstract][Full Text] [Related]
19. Lung cancer: Resolving resistance to ALK-targeted therapy.
Hutchinson L
Nat Rev Clin Oncol; 2016 Feb; 13(2):64. PubMed ID: 26806320
[No Abstract] [Full Text] [Related]
20. Sequential Use of Anaplastic Lymphoma Kinase Inhibitors in Japanese Patients With ALK-Rearranged Non-Small-Cell Lung Cancer: A Retrospective Analysis.
Asao T; Fujiwara Y; Itahashi K; Kitahara S; Goto Y; Horinouchi H; Kanda S; Nokihara H; Yamamoto N; Takahashi K; Ohe Y
Clin Lung Cancer; 2017 Jul; 18(4):e251-e258. PubMed ID: 28065466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
